| Course | NR 546 Advanced Pharmacology: Psychopharmacology for the Psychiatric-Mental Health Nurse Practitioner |
|---|---|
| Week | 5 |
| Paper type | Case analysis |
| Length | About 1,130 words, 2 pages |
| Format | APA 7 student paper |
| School | Chamberlain University |
| Program | MSN, Psychiatric-Mental Health Nurse Practitioner (PMHNP) |
| Updated | September 2026 |
Free sample paper for NR 546 Week 5
Case Analysis: A Partial Response to Escitalopram That Stalled at Week Ten, With Dose, Duration, Adherence, Interactions and the Diagnosis Tested in Order Before Any Change to the Drug
Student Name
College of Nursing, Chamberlain University
NR 546: Advanced Pharmacology: Psychopharmacology for the Psychiatric-Mental Health Nurse Practitioner
Instructor Name
Month Day, Year
Case Analysis: A Partial Response to Escitalopram That Stalled at Week Ten, With Dose, Duration, Adherence, Interactions and the Diagnosis Tested in Order Before Any Change to the Drug
The Picture and the Timeline
The patient is the teacher from earlier weeks, in a first depressive episode with anxious distress, who started escitalopram 5 mg ten weeks ago and moved to 10 mg on day 8. The course so far:
Baseline: PHQ-9 18, GAD-7 13. Week 4: PHQ-9 14, GAD-7 10; mild nausea in the first week had settled; stools slightly looser; mildly delayed orgasm reported. Week 6: PHQ-9 12. The plan called for an increase to 20 mg, but the patient asked to wait, worried that a higher dose would worsen the bowel and sexual effects. The dose stayed at 10 mg. Week 10 (today): PHQ-9 11, GAD-7 8.
What has moved: worry is less constant, the patient is planning lessons again and has had no passive death wishes for four weeks. What has not moved: fatigue, poor concentration by early afternoon and sleep that feels unrefreshing despite no longer waking at 4 a.m. The patient says, "The dark mood lifted, but I'm still exhausted all the time."
An improvement of 7 points, about 39% from baseline, is a partial response. The last four weeks show little further change. This analysis asks why before proposing any change to the medication.
Dose and Duration
The first question is whether the trial has been a trial. The patient has taken 10 mg for about nine weeks, which is long enough to judge that dose. But 10 mg is the usual starting dose of escitalopram, and the plan had intended an increase to 20 mg at week 6 for a response under 50%. The dose, not the duration, is the first gap. In the large sequential treatment study of outpatients with depression, protocol-driven dose increases for patients without sufficient response were part of each treatment step, and many patients reached remission only after adequate dosing over a longer period (Rush et al., 2006). This patient has not yet had the dose the plan specified.
Dose alone, however, is unlikely to explain the particular pattern, in which mood and worry improved while fatigue, concentration and unrefreshing sleep did not.
Adherence
When asked about missed tablets over the last seven days, the patient counts two, and that this is typical. The dose is taken in the morning, and on rushed mornings before early classes it is forgotten. The patient has not been skipping doses deliberately and has not stopped for side effects. Missing two of seven doses of a drug with a half-life of about 27 to 32 hours (Stahl, 2021) produces fluctuating levels and, in some patients, mild discontinuation symptoms such as dizziness or irritability on the second missed day. The patient recognizes feeling "foggy" on some Mondays.
Adherence is therefore a real contributor, and its cause is practical rather than motivational. Moving the dose to the evening, tying it to an existing routine or using a weekly pill organizer are likely to help. Escitalopram can be taken at either time of day.
Interactions and Substances
The medication list is unchanged: escitalopram, sumatriptan about twice a month and ibuprofen occasionally. None reduces escitalopram levels. Alcohol remains at about two glasses of wine most evenings. Alcohol worsens sleep quality, particularly in the second half of the night, and can blunt response to antidepressants. It is a plausible contributor to the unrefreshing sleep and daytime fatigue, and it has not changed since baseline, when it was recorded but not addressed.
The Diagnosis Reconsidered
The residual symptoms, fatigue, poor concentration and unrefreshing sleep, are common in partially treated depression. They are also the core symptoms of several medical conditions, and the question is whether something other than depression is producing them.
Thyroid function was normal at baseline. There is no history suggesting bipolar disorder, and the improvement pattern does not suggest a mixed state. On direct questioning today, however, the patient reports that their partner complains of loud snoring and has twice noticed pauses in breathing at night. The patient's Epworth Sleepiness Scale score is 13, indicating excessive daytime sleepiness, and the body mass index is 32. These findings raise the possibility of obstructive sleep apnea. In a longitudinal population study, sleep-disordered breathing was associated with an increased risk of developing depression, with a dose-response relationship (Peppard et al., 2006). Untreated sleep apnea could explain why fatigue and concentration have not improved while mood has.
Two explanations are therefore live: an escitalopram dose below the planned level, with inconsistent adherence, and a probable untreated sleep disorder contributing to the residual symptoms, possibly worsened by evening alcohol.
The Proposal
Each proposal is tied to the explanation it addresses.
For adherence: move escitalopram to the evening with the patient's evening routine, and use a weekly pill organizer. No change to the drug itself.
For dose: once adherence is consistent for two weeks, increase escitalopram to 20 mg daily, as the original plan intended. The patient's concern about side effects is addressed directly: the bowel and sexual effects at 10 mg have been mild, and if either worsens significantly at 20 mg the dose can return to 10 mg, or bupropion can be added.
For the diagnosis: refer for a sleep study to assess for obstructive sleep apnea. If confirmed, treatment may improve fatigue, concentration and possibly mood in its own right.
For alcohol: discuss the effect of evening alcohol on sleep and mood, and agree on a goal of no alcohol on work nights for the next four weeks.
The medication is not switched today. Switching would discard a partial response and would not address either adherence or a sleep disorder. Review is set at four weeks after the dose increase, with PHQ-9, GAD-7, the suicide screen, adherence and the sleep study result.
The order of the changes matters. Adherence is fixed first because an increase in dose cannot be judged if the patient takes the drug on only five days a week. The sleep study proceeds in parallel, since it takes several weeks to arrange and does not interfere with medication changes. The alcohol goal starts at once because it costs nothing and may improve sleep within days. If all four steps are taken and the PHQ-9 is still above 10 at the next review, a switch or augmentation becomes the right conversation, with the ordinary explanations already set aside.
References
Peppard, P. E., Szklo-Coxe, M., Hla, K. M., & Young, T. (2006). Longitudinal association of sleep-related breathing disorder and depression. Archives of Internal Medicine, 166(16), 1709-1715. https://doi.org/10.1001/archinte.166.16.1709
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., McGrath, P. J., Rosenbaum, J. F., Sackeim, H. A., Kupfer, D. J., Luther, J., & Fava, M. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. American Journal of Psychiatry, 163(11), 1905-1917. https://doi.org/10.1176/ajp.2006.163.11.1905
Stahl, S. M. (2021). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (5th ed.). Cambridge University Press.
The Chamberlain NR 546 Week 5 instructions
The fifth week asks you to analyze a case in which a patient has responded only partly to treatment. Most prompts call for a summary of the case and timeline, possible explanations for the partial response, assessment of each, and a management plan with rationale. Lay out what has changed and what has not, with dates and scores. Then test the ordinary explanations in order: whether the dose has been adequate, whether the duration has been adequate, whether the patient is taking the drug, whether anything is interfering with it and whether the diagnosis is right. Treat adherence as a clinical question with practical causes. Review the full medication and substance list. Propose changes tied to the explanations that survive, not a reflex switch. Cite treatment and diagnostic evidence in APA 7.
Inside the NR 546 Week 5 example
The analysis opens with the timeline: PHQ-9 from 18 to 11 over ten weeks, mood and worry improved, fatigue and poor concentration unchanged, and a planned dose increase deferred at the patient's request. The dose section finds 10 mg below the planned level, citing a large sequential treatment study. The adherence section finds two missed doses a week on rushed mornings and foggy Mondays. The interactions section finds no interfering drugs but unaddressed evening alcohol. The diagnosis section reviews thyroid and bipolar possibilities and then identifies probable obstructive sleep apnea, citing a longitudinal study linking sleep-disordered breathing and depression. The proposal ties evening dosing, a later increase to 20 mg, a sleep study and an alcohol goal to each explanation and explains their order.
Reading the NR 546 Week 5 grading rubric
Partial response analyses are commonly assessed on a clear timeline, systematic evaluation of possible explanations, attention to adherence and interactions, reconsideration of the diagnosis and a plan tied to the findings. Testing explanations in a logical order before changing the drug shows the discipline the week is built around. Checking whether the dose matched the plan catches a common gap. Treating adherence as a practical problem rather than a patient failing reads as professional. Reconsidering the diagnosis, and finding a medical contributor, shows breadth. A proposal in which each change addresses a specific explanation, in a sensible order, earns the strongest marks. Evidence on treatment steps and on the relevant medical condition, cited in APA 7, supports the plan.
NR 546 Week 5 help from the desk
Analyses often switch the medication in the first paragraph, discarding a partial response without asking why it stalled. Test the ordinary explanations first. Another weakness is accepting the dose and duration without checking them against the plan. Some writers mention adherence only to note that the patient should take the drug, missing the practical reasons for missed doses. Ask how many doses were missed and why. Review alcohol and other substances. Reconsider the diagnosis, since residual symptoms such as fatigue can come from a medical condition. Avoid proposing several unrelated changes with no order. Tie each proposal to an explanation, and say what would lead you to switch or augment if the ordinary explanations are addressed and the response still falls short.
Get a NR 546 Week 5 example written to your instructions
Send the Week 5 instructions and the case your section supplies, and a custom example is written to that patient and returned inside 24 to 48 hours. The first one is free. Any patient of your own stays yours to describe, and only with the identifiers taken out.
More NR 546 papers and PMHNP samples
- NR 546 Week 1: Antidepressant Timing Discussion
- NR 546 Week 2: Receptor Mechanism Write-Up
- NR 546 Week 3: Medication Selection Rationale
- NR 546 Week 4: Titration and Monitoring Plan
- NR 546 Week 6: Adverse Effect Brief
- NR 546 Week 7: Medication Education Handout
- NR 546 Week 8: Psychopharmacology Case Paper
NR 546 Week 5 questions, answered
How long counts as an adequate trial?
It depends on the agent and the target, and your section will expect the answer sourced rather than assumed. What matters more for the grade is that the question gets asked at all, with the case timeline set against whatever interval your reference supports. An analysis that declares a failure without checking duration loses more than one citing a slightly generous interval.
Should I address adherence if the case does not mention it?
Yes, at least to say it was not reported and what you would ask. Silence reads as an assumption. Where the case does supply hints, such as cost, side effects or a complicated schedule, those are usually planted deliberately and a grader is checking whether they were noticed and connected to the response.
Can the answer be to change nothing?
Often, and it is sometimes the correct answer, particularly where the trial has been too short. A well argued decision to continue and review, with the interval and the criteria stated, reads as clinical judgment. What loses marks is continuing by default without arguing for it, which looks the same on paper as not having decided.
Where can I find a free NR 546 Week 5 sample paper?
The stalled escitalopram response analysis is published above as the NR 546 Week 5 sample, open in full on this page. If your case has a different pattern of response, give us the timeline and an analysis testing each explanation can be prepared.
What order should NR 546 Week 5 test explanations in?
Dose, duration, adherence, interactions and the diagnosis, before any change to the drug. The sample finds an unraised dose, missed doses and probable sleep apnea.